Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Clinical significance of pulmonary metastases in stage D2 prostate cancer patients

Prostate Cancer and Prostatic Diseases volume 5, pages 159–163 (2002)Cite this article

Abstract

Several prognostic factors such as the extent of bone metastases (EOD) in advanced prostate cancer (PCa) have been reported. Metastasis of the lung is rarely a significant clinical factor in the management of prostate cancer. The present study evaluates the clinical significance of lung metastases. We retrospectively reviewed the PCa database to identify patients with pulmonary metastases at initial diagnosis. The medical records of the patients were examined with respect to age, histologic grade, EOD score, marker response to endocrine therapy and clinical outcome. We then compared several potential clinical factors between patients with and without pulmonary metastases. Next, we retrospectively reviewed autopsy records of 60 Japanese patients who died of hormone-refractory metastatic PCa with particular focus upon metastatic profiles. A comparative study of stage D2 patients with (n=20) and without (n=77) pulmonary metastases found no significant differences in EOD score, performance status, marker response and survival. Only tumor grade was better in the group with, than without pulmonary metastases (P=0.0120, chi-square analysis). In the series of autopsies, we found pulmonary metastases in 38 cases (63%), following metastases of the bone (57 cases, 95%) and lymph nodes (52 cases, 87%). A retrospective analysis of survival showed that patients with bone or lymph node metastases had a positive relative risk. In contrast, lung metastasis could be a positive prognostic indicator, although the findings were not statistically significant. These data suggest that the presence of pulmonary metastasis has no ominous impact on clinical course and disease outcome even in patients with disseminated prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Kakizoe T . Figures on Cancer in Japan–1995 Foundation for Promotion of Cancer Research: Tokyo 1995 (in Japanese)

    Google Scholar 

  2. Rarker SL, Tong T, Bolden S, Wingo PA . Cancer Statistics CA Cancer J Clin 1997 47: 5–27

    Article  Google Scholar 

  3. Huggins C, Hodges CV . Studies on prostate cancer, effects of castration, of estrogens and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate Cancer Res 1941 1: 293–297

    CAS  Google Scholar 

  4. Resnick MI, Grayhack JT . Treatment of stage IV carcinoma of the prostate Urol Clin North Am 1978 5: 141–161

    Google Scholar 

  5. Ishikawa S, Soloway MS, Van der Zwaag R, Todd B . Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer J Urol 1989 141: 1139–1142

    Article  CAS  Google Scholar 

  6. Mulders PF et al. Analysis of prognostic factors in disseminated prostatic cancer. An update Cancer 1990 65: 2758–2761

    Article  CAS  Google Scholar 

  7. Soloway MS . The importance of prognostic factors in advanced prostate cancer Cancer 1990 66: 1017–1021

    Article  CAS  Google Scholar 

  8. Ernst DS, Hanson J, Venner PM . Uro-Oncology Group of Northern Alberta Analysis of prognostic factors in men with metastatic prostate cancer J Urol 1991 146: 372–376

    Article  CAS  Google Scholar 

  9. Chodak GW et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer JAMA 1991 265: 618–621

    Article  CAS  Google Scholar 

  10. Matzkin H et al. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen Cancer 1993 72: 1286–1290

    Article  CAS  Google Scholar 

  11. Matzkin H, Perito PE, Soloway MS . Prognostic factors in metastatic prostate cancer Cancer 1993 72: 3788–3792

    Article  CAS  Google Scholar 

  12. Jorgensen T et al. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian prostatic cancer group study–2 J Urol 1997 158: 164–170

    Article  CAS  Google Scholar 

  13. Imamoto T et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer Endocrine J 2001 48: 573–578

    Article  CAS  Google Scholar 

  14. Isshiki S et al. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy in prostate cancer J Urol 2002 167: 512–515

    Article  CAS  Google Scholar 

  15. Akimoto S et al. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis Eur Urol 1998 34: 142–147

    Article  CAS  Google Scholar 

  16. Bubendorf L et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients Hum Pathol 2000 31: 578–583

    Article  CAS  Google Scholar 

  17. Viadana E, Bross IDJ, Pickren JW . The metastatic spread of kidney and prostate cancers in men Neoplasma 1976 3: 323–332

    Google Scholar 

  18. Saitoh H et al. Two different lymph node metastatic patterns of a prostatic cancer Cancer 1990 65: 1843–1846

    Article  CAS  Google Scholar 

  19. Varkarakis MJ et al. Lung metastases in prostatic carcinoma, clinical significance Urology 1974 3: 447–452

    Article  CAS  Google Scholar 

  20. Fabozzi SJ, Schellhammer PF, El-Mahdi AM . Pulmonary meta-stases from prostate cancer Cancer 1995 75: 2706–2709

    Article  CAS  Google Scholar 

  21. Karnofsky DA . Determining the extent of the cancer and clinical planning for cure Cancer 1968 22: 730–734

    Article  CAS  Google Scholar 

  22. Soloway MS et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 1988 61: 195–202

    Article  CAS  Google Scholar 

  23. Isaacs JT . The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999 26: 263–273

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Ministry of Education, Science, Technology and Culture (11770882, 11671536 and 13671635), the Inohana Foundation (Chiba University), the Japanese Urological Association (2000), and the Japanese Society of Strategies for Cancer Treatment and Research (2001).

Author information

Authors and Affiliations

  1. Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan

    H Nakamachi, H Suzuki, K Akakura, T Imamoto, T Ueda, M Ishihara, Y Furuya, T Ichikawa, T Igarashi & H Ito

Authors
  1. H Nakamachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Akakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Imamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Ishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Furuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Igarashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Suzuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamachi, H., Suzuki, H., Akakura, K. et al. Clinical significance of pulmonary metastases in stage D2 prostate cancer patients. Prostate Cancer Prostatic Dis 5, 159–163 (2002). https://doi.org/10.1038/sj.pcan.4500573

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500573

Keywords

This article is cited by

Search

Advanced search

Quick links